Treatment Interrupts Depression Early

Who is this study for? Youth with first episode depression
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug, Behavioral
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The TIDE project aims to establish personal indicators for initial treatment choice for youth with first episode depression. Specifically, 100 adolescents and young adults (age 12 to 25) with untreated major depressive disorder of recent onset will be randomly allocated in 1:1 ratio to one of two evidence-based regimens for youth depression: (A) Individual cognitive-behavioural therapy; and (B) Optimized pharmacological treatment with an antidepressant. All participants will be offered active treatment for up to 1 year and follow-up for 2 years to establish short- and long-term outcomes, including change in depressive symptoms, maintenance of remission, core role functioning, achievement of educational, occupational and social milestones, and quality of life. Baseline characteristics including duration of untreated depression, pre-existing anxiety, attention-deficit/hyperactivity disorder, substance use, symptoms of reduced interest and activity, sleep, rhythm and melody of speech, brain function, history of childhood adversity, coping style, repetitive thinking, and family history of depression and bipolar disorder will be tested as potential moderators of outcome. Characteristics that differentially predict outcomes in those allocated to initial cognitive-behavioural therapy and those allocated to initial treatment with antidepressants will be combined into a personalized allocation algorithm.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 25
Healthy Volunteers: f
View:

• Age 12-25 years

• Diagnosis of major depressive disorder, onset of the major depressive disorder within the last 12 months. Depression considered the most significant problem in need of treatment.

• An additional inclusion criterion for entering Stage 1 (active intervention) is a minimum moderate depression severity (CDRS-R≥40; MADRS≥20) that justifies the need for treatment. Individuals who fulfill general inclusion criteria but are below the depression severity threshold for active intervention will still be eligible to participate in follow-up assessments.

• Verbal ability sufficient to participate in psychological treatment.

Locations
Other Locations
Canada
Nova Scotia Health
RECRUITING
Halifax
Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal / Centre de Recherche Douglas (Montreal West Island IUHSSC / Douglas Research Center)
RECRUITING
Montreal
Contact Information
Primary
Rudolf Uher, MD, PhD
uher@dal.ca
902-473-7209
Backup
Jill Cumby, RN, MN
jill.cumby@nshealth.ca
902-473-1781
Time Frame
Start Date: 2021-12-02
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 100
Treatments
Experimental: Psychotherapy
Cognitive-behavioural therapy
Experimental: Pharmacotherapy
Antidepressant medication
Related Therapeutic Areas
Sponsors
Leads: Nova Scotia Health Authority

This content was sourced from clinicaltrials.gov